CA3026142C - Crystalline form of compound suppressing protein kinase activity, and application thereof - Google Patents
Crystalline form of compound suppressing protein kinase activity, and application thereof Download PDFInfo
- Publication number
- CA3026142C CA3026142C CA3026142A CA3026142A CA3026142C CA 3026142 C CA3026142 C CA 3026142C CA 3026142 A CA3026142 A CA 3026142A CA 3026142 A CA3026142 A CA 3026142A CA 3026142 C CA3026142 C CA 3026142C
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- disease
- compound
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/084300 | 2016-06-01 | ||
| CNPCT/CN2016/084300 | 2016-06-01 | ||
| PCT/CN2017/086760 WO2017206924A1 (zh) | 2016-06-01 | 2017-06-01 | 抑制蛋白激酶活性化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3026142A1 CA3026142A1 (en) | 2017-12-07 |
| CA3026142C true CA3026142C (en) | 2024-02-13 |
Family
ID=60477983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3026142A Active CA3026142C (en) | 2016-06-01 | 2017-06-01 | Crystalline form of compound suppressing protein kinase activity, and application thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10899744B2 (https=) |
| EP (1) | EP3470410B1 (https=) |
| JP (1) | JP7054528B2 (https=) |
| KR (1) | KR102466958B1 (https=) |
| CN (1) | CN109195964B (https=) |
| AU (1) | AU2017274110B2 (https=) |
| CA (1) | CA3026142C (https=) |
| EA (1) | EA201892687A1 (https=) |
| ES (1) | ES2981015T3 (https=) |
| IL (1) | IL263356B (https=) |
| MY (1) | MY188379A (https=) |
| PH (1) | PH12018502529A1 (https=) |
| PL (1) | PL3470410T3 (https=) |
| RU (1) | RU2744264C2 (https=) |
| SG (1) | SG11201810800VA (https=) |
| TW (1) | TWI646094B (https=) |
| WO (1) | WO2017206924A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279579B2 (en) | 2018-06-21 | 2023-02-01 | Betta Pharmaceuticals Co Ltd | Crystalline form of a compound to inhibit the activity of cdk4/6 and its use |
| EP4188922A1 (en) | 2020-08-03 | 2023-06-07 | Teva Pharmaceuticals International GmbH | Solid state forms of ensartinib and ensartinib salts |
| EP4385510A4 (en) * | 2021-08-10 | 2025-08-20 | Betta Pharmaceuticals Co Ltd | USE OF ENSARTINIB OR A CORRESPONDING SALT IN THE TREATMENT OF A DISEASE CARRYING A MET EXON 14 SKIPPING MUTATION |
| KR102851417B1 (ko) * | 2022-08-16 | 2025-08-28 | 제이투에이치바이오텍 (주) | 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL358271A1 (pl) * | 2000-03-06 | 2004-08-09 | Warner-Lambert Company | 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| US8414489B2 (en) | 2003-11-13 | 2013-04-09 | Medtronic Minimed, Inc. | Fabrication of multi-sensor arrays |
| ME01309B (me) * | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
| BRPI0514687A (pt) | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
| KR101146852B1 (ko) * | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| CN101652068A (zh) * | 2007-01-19 | 2010-02-17 | 艾科睿制药公司 | 激酶抑制物化合物 |
| ES2670665T3 (es) * | 2008-06-19 | 2018-05-31 | Xcovery Holding Company Llc | Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de quinasa |
| EA024809B1 (ru) * | 2010-10-08 | 2016-10-31 | Икскавери Холдинг Кампани, Ллс | Замещенные соединения пиридазинкарбоксамида |
| WO2012048258A2 (en) * | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
-
2017
- 2017-05-31 TW TW106117900A patent/TWI646094B/zh active
- 2017-06-01 WO PCT/CN2017/086760 patent/WO2017206924A1/zh not_active Ceased
- 2017-06-01 PL PL17805869.9T patent/PL3470410T3/pl unknown
- 2017-06-01 ES ES17805869T patent/ES2981015T3/es active Active
- 2017-06-01 KR KR1020187038142A patent/KR102466958B1/ko active Active
- 2017-06-01 IL IL263356A patent/IL263356B/en unknown
- 2017-06-01 EP EP17805869.9A patent/EP3470410B1/en active Active
- 2017-06-01 SG SG11201810800VA patent/SG11201810800VA/en unknown
- 2017-06-01 CN CN201780006852.3A patent/CN109195964B/zh active Active
- 2017-06-01 JP JP2018563619A patent/JP7054528B2/ja active Active
- 2017-06-01 MY MYPI2018002245A patent/MY188379A/en unknown
- 2017-06-01 CA CA3026142A patent/CA3026142C/en active Active
- 2017-06-01 US US16/306,104 patent/US10899744B2/en active Active
- 2017-06-01 RU RU2018145183A patent/RU2744264C2/ru active
- 2017-06-01 EA EA201892687A patent/EA201892687A1/ru unknown
- 2017-06-01 AU AU2017274110A patent/AU2017274110B2/en active Active
-
2018
- 2018-11-29 PH PH12018502529A patent/PH12018502529A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1259249A1 (zh) | 2019-11-29 |
| TWI646094B (zh) | 2019-01-01 |
| ES2981015T3 (es) | 2024-10-04 |
| AU2017274110B2 (en) | 2021-05-06 |
| MY188379A (en) | 2021-12-07 |
| JP2019518026A (ja) | 2019-06-27 |
| JP7054528B2 (ja) | 2022-04-14 |
| NZ750921A (en) | 2024-12-20 |
| EP3470410B1 (en) | 2024-04-17 |
| PH12018502529A1 (en) | 2019-04-08 |
| BR112018074612A2 (pt) | 2019-03-19 |
| CA3026142A1 (en) | 2017-12-07 |
| EP3470410A4 (en) | 2019-12-04 |
| TW201742865A (zh) | 2017-12-16 |
| RU2018145183A3 (https=) | 2020-07-16 |
| EA201892687A1 (ru) | 2019-06-28 |
| RU2744264C2 (ru) | 2021-03-04 |
| IL263356B (en) | 2022-08-01 |
| RU2018145183A (ru) | 2020-07-14 |
| SG11201810800VA (en) | 2019-01-30 |
| CN109195964B (zh) | 2021-08-10 |
| CN109195964A (zh) | 2019-01-11 |
| US20190135792A1 (en) | 2019-05-09 |
| AU2017274110A1 (en) | 2019-01-24 |
| IL263356A (en) | 2018-12-31 |
| PL3470410T3 (pl) | 2024-09-16 |
| EP3470410A1 (en) | 2019-04-17 |
| KR102466958B1 (ko) | 2022-11-14 |
| US10899744B2 (en) | 2021-01-26 |
| KR20190012231A (ko) | 2019-02-08 |
| WO2017206924A1 (zh) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3292115B1 (en) | Crystalline form of fused pyridine derivative's maleate and uses thereof | |
| JP2020007327A (ja) | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 | |
| CN106146583B (zh) | 新型胞苷衍生物及其应用 | |
| CN117866030A (zh) | 用于治疗癌症的环状二核苷酸化合物 | |
| CA3026142C (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
| WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| TW202411219A (zh) | 雜環化合物ccr4抑制劑及其用途 | |
| CN105705494B (zh) | 喹唑啉衍生物及其药物组合物，以及作为药物的用途 | |
| CN104341434B (zh) | 取代的雷帕霉素三氮唑衍生物和用途 | |
| CN103373986B (zh) | 克里唑替尼前药及其制备方法与用途 | |
| JP7755347B2 (ja) | 腎癌の標的治療のための新規化合物及び組成物 | |
| AU2022275275A1 (en) | Polymorph of imidazolidinone compound, preparation method therefor and use thereof | |
| NZ788961A (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
| WO2016078397A1 (zh) | 新型胞苷衍生物及其应用 | |
| EA041596B1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| HK1259249B (zh) | 抑制蛋白激酶活性化合物的晶型及其应用 | |
| BR112018074612B1 (pt) | Compostos intermediários, composto que suprime a atividade de proteína quinase, sua forma cristalina, método de produção, composição farmacêutica e aplicação da forma cristalina | |
| KR20130141469A (ko) | 피라졸릴아미노퀴나졸린의 브롬화수소 염 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220317 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250521 |